INDEX

Aβ plaques, 132. See also Amyloid-beta (Aβ) neuropathology; β-amyloid plaques
Aberrant myelination, 78
Abnormal protein accumulation, in dog brain regions, 132
Absolute size distribution, 225
Accelerated aging studies, central problem with, 130
Accessory olfactory bulb (AOB), 429, 442
Accessory olfactory formation (AOF), 188
Accuracy (ACC), 119, 120
Acetylcholinesterase (AChE) activity, depression of, 496
3-Acetylpyridine (3-AP), 107–108
Acidophilic neurons, 9, 192
Acrylamide, 109, 377
Activity measures, 106
Acute cell death, 152–154
Acute dosing, 152
Acute eosinophilic neuron degeneration, 192
Acute evaluations, 154
Acute metabolic arrest, 491
Acute neurotoxins, 153
Acute response, cell death due to, 153
Adenovirus encephalitis, 469
Adult nervous system, evaluation of, 321–338
Adult neural arrangement, pace of, 69–70
Adverse behavioral changes, 109–110
Afferent neurons, 15
Affymetrix Genechip, 295, 299
Age. See also Aging
  oxidative damage and, 131–132
  in predicting Aβ accumulation, 132
Aged dogs, clustering by cognitive ability, 131
Age-related cognitive decline, 128
Age-related macular degeneration (ARMD), 389, 390
Age-related neurological diseases, 81
Agilent microarray chip technology, 295
Aging. See also Behavioral aging; Human aging
  Alzheimer’s disease and, 125–127
  animal, 125
  genetic models of, 129–130
  impact on brain structure/function, 125–138
  successful versus pathologic, 128
Alar plates, 68
Albuminocytologic dissociation, 279
Alicaraé, Ana, xi, 463
Alcohol, cell destruction by, 143, 145
Allergic neuritis, experimental, 380
Allometric relationship, 343
Alphaviruses, 265
Altricial animals, 340
Altricial species, 70
Alzheimer, Alois, 4
Alzheimer astrocytes
  type I, 467
  type II, 467, 477
Alzheimer’s disease (AD), 125
  animal models of, 127–132
  common form of, 126
  environmental neurotoxicants and, 132–133
  hallmark features of, 126–127
  human aging and, 125–127
  neuron loss and, 131
Alzheimer’s disease mouse models, imaging, 259
Amino CuAg method, 186–187. See also Cupric silver entries
Aminoglycoside antibiotics, 421–422
Aminoglycosides, ototoxic potential of, 422
Amitriptyline, 456
D-Amphetamine, neurotoxicity of, 145
Amphetamine exposure, in rats, 10
Amyloid-beta (Aβ) neuropathology, 126–127, 132. See also
  Aβ plaques; β-amyloid plaques
Amyotrophic lateral sclerosis (ALS), 376
Analytical procedures, for studying the inner ear, 417–418
Anaplastic tumors, malignant, 381
Anatomical changes, related to developmental age, 73
Anatomical organization, in the developing nervous system, 63–64

Anatomic Gene Expression Atlas (AGEA), 310, 313, 314
Anencephaly, 16, 80
Anesthetics, local, 453
Angiogenesis, 80
Angiogenic factors, 405
Angiography, fluorescein, 389
Animal model applications, microPET and microSPECT, 257–259
Animal models
of human aging and Alzheimer’s disease, 127–132
relevance to humans, 120–121
of spinal drug delivery, 457–458
Animal nervous systems, in vivo imaging for, 253–269
Animal numbers, guidelines for, 502
Animals. See also Bird; Carnivore model; Chicken brain sections; Dog entries; Equine leukoencephalomalacia; Large animal entries; Mammalian entries; Mice; microPET/microSPECT animal model applications; Monkey entries; Mouse Brain Gene Expression Map (BGEM); Nonhuman primate entries; Primate entries; Rat entries; Rodent entries; Transgenic animals; Vertebrates; Veterinary entries aging of, 125
altricial and precocial, 340
brain removal from, 326
light-producing transgenic, 262
naming neural structures in, 7
Animal sacrifice
periodic intervals of, 154
timing of, 151–154
Animal subjects, brain imaging in, 254–255
Animal vascular patterns, 387–388
Annotation databases, 310, 311
Ante mortem neurological evaluations, veterinary, 487–488
Anterior olfactory nucleus (AON), 310, 311
Anterior olfactory nucleus (AON), 434
Antonyms, Douglas C., xi, 475
Antibiotics, aminoglycoside, 421–422
Antibodies, for detecting myofiber types, 242
Anti-BrdU antibodies, 436
Antigens, in rat olfactory mucosa, 432
Antiglial fibrillary acidic protein (GFAP), 9
Antioxidant mechanisms, in ocular tissues, 399
Antisense RNA (aRNA), 289
Apoptosis, 79. See also Cell death entries
detection of developmental, 177
imaging, 261
Archicortex model, 69
Archipallium, 22–23
Area, estimation of, 215
Area centralis, 386–387
Argyrophilic dark neurons, 195. See also Silver entries
Arsenic exposure, 480
Artemether, 376
Arterial blood supply
to the brain, 24–25
to the spinal cord, 24, 25
Arteries
carotid, 24, 25
vertebral, 24–25
Artifacts
instrument-induced, 161
involving myelin, axons, and sensory ganglion neurons, 197–199
minimizing, 242–243
miscellaneous, 199–200
overinterpreting, 469
in veterinary histological preparations, 490–491
Artificial staining, 189
Ascending reticular activating system (ARAS), 29
Associative learning, 116
Astrocyte perturbation, 154
Astrocytes, 466. See also Alzheimer astrocytes
gemistocytic, 492
in neural lesion genesis, 492
normal versus reactive, 184
perturbed, 183
staining, 335
Astrocytic labeling, 177
Astrocytoma, 470–471
Astrocytosis, 466–467
Atlases. See Brain atlases; Cancer genome atlas; Comparative neuroanatomy atlas; Digital atlas databases; Gene Atlas; Gene Expression Nervous System Atlas (GENSAT); Neuroanatomic atlases; Text-based neuroanatomic atlases
Atrophy
axonal, 205
identifying, 251
optic nerve, 408
photoreceptor, 403
retinal, 405, 406
of stria vascularis, 424
Attention, defined, 115
Auditory function measurement, 107
Autofluorescence (AF), 167, 389
of erythrocytes, 161, 167
Autofluorescence photography, 389
Automated physical fractionator, 220
Autonomic function abnormalities, 91–94
Autonomic nervous system (ANS), 365–367
assessing elements of, 235
Autonomic nervous system components, harvesting, 328
Autonomic nervous system sectioning, degree of, 332
Avian neuroanatomy, 72. See also Birds
Axonal atrophy, 205, 573
Axonal degeneration, 109, 407–408, 477–478
secondary, 372
Axonal distortion, 199
Axonal dystrophy, 205
Axonal lesions, 374
Axonal size distribution, estimate of, 225
Axonal swelling, 484
Axonal transport, 367
Axonopathies, 109, 368
distally accentuated, 370
in dogs, 377–378
mutant model of, 378
neurofilamentous, 378
neuronal injury, 484–485
in the peripheral nervous system, 377–378
primary, 372
proximal and distal, 378
toxic, 378, 496–497
of unmyelinated nerve fibers, 378
Axon profiles, 225
Axon reaction, 371
Axons
destruction of, 141
disintegrating, 185, 188
myelinated and unmyelinated, 231
neurotoxicants that injure, 496–497
regeneration of, 369–371
serotonergic, 183
Axon terminals, destruction of, 141

“Azide response,” 390

Background staining, evaluation of, 188–189

Baclofen, 452

Bands of Büngner, 369. See also von Büngner band

Basal cell hyperplasia, in olfactory mucosa, 441

Basal (stem) cells, olfactory, 430

Basal metabolic rate, zonal variations in, 8

Basal nuclei, 22

avian, 24

Basal plates, 68

Basophilic neurons, 192–197

Behavior(s)

gender-related differences in, 72

modeling, 117–120

sensitivity to acute pharmacological effects, 110

Behavioral aging

features of, 133

in rodents, 128

Behavioral assays, 105

Behavioral changes

Aβ plaques and, 132

adverse, 109–110

Behavioral endpoints, in neurotoxicity assessment, 139

Behavioral evaluations, 105, 107

Behavioral model systems, for evaluating neuropathology, 105–113

Behavioral outcomes, noncorrelation with pathology outcomes, 110–111

Behavioral tests, 487

advantages and limitations of, 110

common, 106–107

Bergmann cells, 22

β-amyloid plaques, detection of, 177. See also Aβ plaques; Amyloid-beta (Aβ) neuropathology

Biases, related to toxicant-induced alterations, 9

Bier, Augustus, 451

Bioassays, neurotoxicity, 69

Biochemical analysis

of CSF, 278, 279–280

in skeletal muscle sample processing, 243, 249

Biochemical disparities, gender-related, 72

Bioinformatics databases, 309–310

Biological replicates, 297

Biological variation, 297

Biomolecular Interaction Network database (BIND), 310, 311–312

Bionanotechnologies, 262

Biopsies, olfactory, 441. See also Epithelial biopsies; Necropsies entries

Birds. See also Avian nervous system; Avian neuroanatomy

basal nuclei of, 24

cerebellum in, 22

cerebral stem in, 24

cortex in, 24

medulla oblongata in, 21

olfactory bulbs in, 24

prosencephalon of, 24

rhombencephalon in, 21

spinal cord in, 20

telencephalon of, 24

ventricular system of, 17–18

Black staining, 185

BLI sensitivity, 263. See also Bioluminescent imaging (BLI)

Block sampling fraction (BSF), 222

Blood–brain barrier (BBB), 73, 79, 272, 276, 452

agents that impair, 498

imaging in rodents, 259

protection from toxicants by, 497

Blood–CSF barrier, 273

Blood–ISF barrier, 272

Blood–nerve barrier, 231

Blood–ocular barrier, 417

Blood supply parameters, 554

Bolon, Brad, xi, xv, 3, 63, 89, 229, 271, 385, 413, 429, 537, 541

Bolus intrathecal drug delivery, 457

Bottom-up analysis, 304

Botulism, 482–483

Bouin’s solution, 393–394

Bowman’s glands, 430, 438

Boyce, Rogely Waite, xi, 209

Brachial plexus, harvesting, 327

Brain, 20–24. See also Blood–brain barrier (BBB); Cerebell- entries; Cerebr- entries; Coronal entries; Immature brain; Hippocamp- entries; Immersion-fixed brains; Medulla oblongata

arterial blood supply to, 24–25

avian, 72

cerebellum, 21–22

correlation of clinical signs and lesion localization in, 91–98

developmental organization of, 65

evaluating coronal levels of, 489

formation of, 16

harvesting, 488

macroscopic examination of, 488

microscopic changes in, xix

neurobiological parameters for, 551–554

neurotoxin targets in, 142–151

organizational features of, 159–160

prosencephalon, 22–24

rhombencephalon and mesencephalon, 20–21

stained features in, 189

vulnerability to neurotoxicants, 8, 63

Brain aging, in rodents, 129

Brain areas, morphometric analysis of, 352–353

Brain atlases, 160, 163, 168

Brain chemistry, changes in, 181–183

Brain damage

locating, 145–146

permanent, 141

Brain fluid flow, 273

Brain functions, modeling, 117–120

Brain growth spurt (BGS), 70

Brain handling procedures, 161

Brain imaging, in animal subjects, 254–255

Brain imaging studies, 131

Brain injury, compensation for, 141

Brain landmark locations, 165

Brain length, of laboratory species, 152

Brain matrix, 164, 165, 166

Brain modalities, 26–27

Brain pathology, safety consideration spectrum in, 140

Brain perturbations/inflammation, evaluation of, 141
Central nervous system tissue, preserving, 463
Central nervous system tissues/fluids, chemical composition of, 555
Central-peripheral distal axonopathy, 484
Central vestibular disease, 98
Cerebellar development, 70
Cerebellar nuclei, 21
Cerebellar pathways, 37
Cerebellar syndrome, 98
Cerebellar system, 36–37
Cerebellum, 16, 17, 20, 21–22
avian, 22, 72
characteristics of, 345–346
major function of, 39
in mammals, 21
structure of, 70
subdivisions of, 22
trimming, 348
Cerebellum sections, 56–57, 61
rat, 167
Cerebral amyloid angiopathy (CAA), 126
in dog brain, 132
Cerebral cortex, defective neuronal migration in, 76
Cerebral cortex structures, prominence of, 70–71
Cerebral edema, 476
Cerebral hemispheres, characteristics of, 344–346
Cerebral plexuses, 21
Cerebral stem, in birds, 24
Cerebral syndrome, 91
Cerebrocerebellum, 37, 39
collateral information from, 39
Cerebrocortical topography, 71
Cerebrospinal fluid (CSF), 16. See also CSF entries
barriers, 272–273
biochemical alterations in, 279–280
biochemical analysis, 278–280
characteristics in neurological disease, 278–280
collecting, 276–277
composition of, 276
cytology, 277–279
normal composition of, 275–276
physiology of, 272–275
physiology of production, circulation, and absorption in, 273–274
removing, 451
sampling and analyzing, 276–278
Cerebrospinal fluid analysis, 271–283
Cervical trauma, 98
Cervicothoracic syndrome, 98
Charcot–Marie–Tooth disease, 379
Charge-coupled devices (CCDs), 263
Chastek paralysis, 499
Chemical change, markers of, 181–183
Chemical Effects in Biological Systems (CEBS) database, 310, 311
Chemical-related health effects, testing guidelines for, 501
Chemical sympathectomy, 375
Chemodectomas, 380
Chemoreceptors, 40
Chewing disease, 498
Chicken brain sections, 46–47, 60–61
Children, developmental neurotoxicity and, 80
Choice response latency (CRL), 119
Cholesterol granulomas, 373
Cholinergic neurons, 183
Choroid plexuses, 17, 18
tumors of, 471
Chromatolysis, 465, 493
Chronic neural diseases, investigating, 8
Chronic studies, temporal sampling in, 154
Circulatory system, control of, 40. See also Blood entries; Vascular entries
Circumventricular organs (CVOs), 273
Clinical neurology, syndrome concept of, 89–101
Clinical signs, correlation with lesion localization, 91–98
Clinical training, in veterinary neurology, 487
Cluster analysis, 300–301
CNS development, impacts on, 339. See also Central nervous system (CNS)
CNS elements, anatomical diversity of, 11
CNS regions, neuron generation in, 73
CNS sections, embedding of, 349
CNS structures, positions of, 69
CNS tissues, susceptibility to handling-induced artifacts, 191
Cocaine. See also Opiates
cerebral perfusion defects and, 478
effects on cerebral blood flow, 256
Coccygeal syndrome, 100
Cochlea, 413, 414–416
Cochleotoxic lesions, 422–423
Code of Federal Regulations (CFR), 521
Coefficient of error (CE), 213–214
Cognition, defined, 115
Cognitive aging. See also Cognitive decline; Cognitive impairment
features of, 133
in dogs, 130–131
Cognitive assessments
experimental manipulations for, 120
modeling functions or behaviors for, 117–120
in nonhuman primates, 115–123
Cognitive decline, in rodents, 128
Cognitive function, aspects of, 115–117
Cognitive function tasks, 117
Cognitive impairment, age-related, 125
Cognitive status, in predicting Aβ accumulation, 132
Collagen pockets, 375
Collateral branch retraction, 79
Collection artifacts, minimizing, 160
Collision-induced dissociation (CID), 307
Color and position discrimination, modeling, 119
Columns, spinal cord, 19
Commercial microarray technologies, versus in-house microarray technologies, 296
Compact myelin, 234
Comparative genomic hybridization (CGH), 293
Comparative neuroanatomy atlas, 45–62
Comparative neurodevelopment, 69–73. See also Structural divergence
Comparative neuropathology, of olfactory mucosa and olfactory brain, 441–442
Complementary DNA (cDNA), 289, 293. See also cDNA arrays
Compliance statement, of a neuropathology report, 507
Computed tomography (CT), 255. See also SPECT-CT imaging
Computerized tasks, 121
Computers, monkey interaction with, 121
Conclusion, in a neuropathology report, 509
Concurrent negative (vehicle) control groups, guidelines for, 502–503
Conditioned position responding (CPR) task, 119, 120
Conduction block, 451
Cones, 386–387
Conscious afferents, 28–32
Conscious proprioception, 30–31
Conscious subjects, imaging, 256–257
Conscious visual perception, 31
INDEX

Continuous drug delivery, 457
Continuous infusion drug delivery, 457
Continuous-wavelength NIRS (CW-NIRS), 265
Contrast agents
gadolinium-based, 260
“smart,” 260–261
Contrast sensitivity, 391–392
Control groups, guidelines for, 502–503
Corning, James Leonard, 451
Coronal brain sections, 143
Coronal planes, 163
Coronal rat brain levels, 148–151
Coronal sectioning, 169
Coronal sections, 145, 146, 321–322, 346 of Wistar rat brains, 350, 351
Corpora amylacea, 125
Corpora quadrigemina, 21
Corpus cerebelli, 22
Corpus striatum, 22, 36
Correlative neurodevelopment, 68–69
Cortex, 22
avian, 24
Cortical atrophy, 125–126
in aging dogs, 131
Cortical functions
interpecies differences in, 71
regimented development of, 68–69
Cortical interneurons, 71
Cortical neuronal basophilia, 490–491
Corticobasal tract, 35
Corticobasal path, 35
Corticohippocampal projection, 35
Cortical areas, 35, 70
Counterstaining, 168
Cranial nerve dysfunction, 94–96, 98
Cranial nerves, 365
harvesting, 327–328
Cresyl violet stain, 194–195
Cryosections, 166
Cryostat sectioning, 248. See also Frozen sections
CSF abnormalities, 271. See also Cerebrospinal fluid (CSF)
CSF absorption, 274
CSF biochemical analysis, 278
in neurological disease, 279–280
CSF biochemical constituents, 275–276
CSF cell analysis, 277–278
in neurological disease, 278–279
CSF cellular constituents, 275
CSF circulation, 452
CSF formation rates, 273
agents influencing, 274
CSF protein concentration, 275, 279
CSF sampling, 271
CSF staining procedures, 277
CSF toxicities, 279
CuAg method, 186–187. See also Cupric silver entries
CuAg stain, 189
Cupric silver degeneration staining, interpretation of, 186, 187
Cupric silver stain, 333
Cupric silver staining method, 185–187. See also Amino CuAg method
C-wave, 390
Cyanide exposure, 479
Cytoarchitectural changes, identifying, 251
Cyto centrifugation, 277
Cytochrome P450 (CYP) family, 432–433
Cytocochleograms, 418
Cytological changes, 476
Cytons, 375
Cytoskeleton, neuronal, 367
Cytotoxic edema, 469
Cytotoxic lectins, 376
Czoty, Paul W., xi, 253
Dark neuron alteration, 192
versus peracute neuronal degeneration, 197
Dark neuron artifacts, 490–491, 515, 516
Dark neurons, 161, 192–197, 326, 342
misinterpretation of, 9
versus degenerating neurons, 194–195
versus eosinophilic neurons, 193
Data, functional observational, 513–514
Data analysis, 299
Database of Interacting Proteins (DIP), 310, 312
Databases
annotation, 310, 311
bioinformatics, 309–310
digital atlas, 310, 313–314
genome-level, 310
microarray, 310, 311
programs for integrating, 310, 312–313
protein interaction, 310, 311–312
protein-level, 310, 311
searching of, 308
sequence-level, 310–311
Data evaluation
EPA guidelines for, 527, 528–529, 532–533
FDA guidelines for, 534
Data normalization, 299
Davidson’s solution, 393–394
DDP. See cis-Platinum (cis-DDP) ototoxicity
Decalcification solutions, 435
Declarative memory, 116–117
Degenerating neurons
histochemical localization of, 171–179
methods for visualizing, 175–176
versus dark neurons, 194–195
Degeneration
axonal, 407–408, 477–478
neuronal, 476
Degenerative staining, 189
Dehydration, of stained slides, 175
Déjérine–Sottas disease, 379
Delayed matching-to-sample (DMTS) task, 119–120
Delayed neurotoxicity, 520
Delayed nonmatching-to-sample (DNMS) test, 121
Dementia, 125. See also Alzheimer’s disease (AD)
Demyelination, 478
immune-mediated, 380
primary, 372–374, 467–468
secondary, 372–374
segmental, 372–373, 380
Dendrites
destruction of, 141
disintegrating, 185, 188
Dendritic extension, 77
Density estimates, 217–218
Design-based stereology, 209–210
Detection, of developmental apoptosis, 177. See also Neurotoxicity detection; Pathological endpoint detection
Detection methods, for gene array technologies, 293–295
Developing nervous system, anatomical organization in, 63–64
Developmental apoptosis, detection of, 177
Developmental neuropathology design, 339–341
examination timepoints in, 340–341
number of animals in, 340
Developmental neurotoxicants, impact of, 74
Developmental neurotoxicity, 80–81, 520–521
guideline for testing, 339
mechanisms of toxicity, 74–80
precursor to adult neurological dysfunction, 80–81
Developmental neurotoxicants, veterinary, 498–499
Developmental neuropathology, 463–473
analytical strategy, 90
basic cellular changes, 464–468
basic parenchymal changes, 468–469
gross examination and tissue collection, 463–464
lysosomal storage diseases, 469
neoplastic diseases, 470–472
viral diseases, 469–470
Diagnostic neuropathology, 463–473
analytical strategy, 90
basic cellular changes, 464–468
basic parenchymal changes, 468–469
gross examination and tissue collection, 463–464
lysosomal storage diseases, 469
neoplastic diseases, 470–472
viral diseases, 469–470
Diagnostic reports, 505
Diencephalic syndrome, 91–94
Diencephalon, 16, 22, 23–24, 65
characteristics of, 345
sectioning scheme for, 465
Dietary neurotoxicants, veterinary, 498–499
Differential gene expression, calculating, 301
Differential interference contrast (DIC) microscopy, 417
Diffusion-weighted MRI (DWI), 261
Digestion chambers, 369
Digital atlas databases, 310, 313–314
online, 314
Direct central nervous system delivery, degree of sectioning for, 330–331
Discussion, in a neuropathology report, 509
Disease mechanisms, discerning, 538
Disector(s), 212, 216–217
optical, 222–224
physical, 219
Disector counting principle, 217
Disector sampling, 218
Disector sections, 220
Disintegrative degeneration stains, 185–187
Dissection, See Gross dissection; Laser capture microdissection (LCM)
Distal axonopathy, 378
Distally accentuated axonopathy, 370
Distribution volume (DV), 255
Distribution volume ratio (DVR), 255
Diuretics, ototoxic effects of, 421
Divalent metal transporter-1 (DMT1), 439
DNA, integrity of, 286–287. See also cDNA arrays; Complementary DNA (cDNA)
DNA damage, in rodent brains, 129
Dog brain sections, 46–59
Dog olfactory mucosa, 431
Dogs
αβ pathology in, 132
brain atlas resources for, 160
breed-specific axonopathies in, 377–378
cognitive aging in, 130–131
decreasing memory in, 130–131
neural lesions in, 495
neurobiological changes in, 131
oxidative damage in, 131–132
Domoic acid, 146
cell destruction by, 143, 145
Domoic acid intoxication, 482
Dopamine (DA), 257
Dopaminergic neurons, 183
agents affecting, 359
Dopaminergic (DA) system, 258
Dopaminergic system imaging, 257
Dopamine system, 254
Dorman, David C., xi, 487
Dorph-Petersen, Karl-Anton, xi, 209
Dorsal root ganglia (DRGs), 16, 229, 346, 365, 377, 453
removal of, 326–327
sampling, 234–235
Dose dependence, of treatment-related effects, 503
Dose–response data, 109, 110
Dosing, acute, 152
Drug clearance, after intrathecal delivery, 452–453
Drug concentration(s)
injectate versus infusate, 452
time course of exposure to, 458
Drug delivery. See also Spinal drug delivery
bolus intrathecal, 457
catheter, 457
continuous infusion, 457
epidural route for, 456–457
long-term, 458
mode of, 457
safety of, 456–459
Drug responsiveness, gender-related differences in, 72
Drugs. See also Spinal drug entries
consequences of, 120
neurotoxic side effects of, 4
Drug study groups, 458–459
“Dying back” neuropathy, 370, 372
Dystrophy, axonal, 205. See also Leukodystrophies
EAAR (excitatory amino acid receptor) agonists, 482
Ear, toxicological neuropathology of, 413–428. See also Hearing; Inner ear; Oto- entries
analytical methods, 417–418
anatomy and physiology, 413–417
Ectopiae, 76, 350
Ectopic neuronal clusters, 351–352
Edema, 476. See also Papilledema
of the central nervous system, 468–469
intramyelinic, 205
myelin, 373
toxic myelin, 380
Edinburgh Mouse Atlas Project (EMAP), 310, 313
EDTA-based decalcifying solutions, 435
Effector organs, 15
Effector organ sampling, 346–347
Efferen neurons, 15
Efferents, 39
Egocentric spatial learning, 130
Eight-section brain trimming scheme, 165–166
Electron micrographs, 205–208
Electron microscopy (EM), 203, 205, 375. See also Transmission electron microscopy (TEM)
retinal preservation for, 397–398
of skeletal muscle, 249–250
Electron microscopy studies, 265
Electrophysiological studies, in vivo, 129
Electroretinography (ERG), 390–391. See also ERG patterns components of, 391
Electrospray ionization (ESI), 304
advantages and limitations of, 308
Elements of Style, The (Strunk & White), 505
Embedding
of CNS sections, 349
of olfactory mucosa, 436
paraffin, 329, 347, 396
of peripheral nerve tissues, 236
plastic, 348, 396–397
Embryonic blood–brain barrier, 79
Embryonic day, 73
Embryonic development, in mammalian prosencephalon, 23
Emetic center, 40–41
Encephalitis, adenovirus, 469
Encephalization, 65
Encephalocoele, 80
Encrusted neurons, 468
Endoneurium, 231
Enervated (Enr) mouse, 379
Enteric nervous system, 40, 367
Enterovirus-induced encephalomyelitis, 377
Entrez Genome database, 310
Enucleation, 392–393
Environmental neurotoxicants, neurodegenerative disease
and, 132–133
Environmental Protection Agency (EPA). See also Environmental Protection Agency (EPA)
delayed neurotoxicity screening guidelines, 527–529
developmental neurotoxicity screening guidelines, 529–533
general neurotoxicology screening guidelines, 523–527
guidelines, 236, 301, 355, 489, 519
test guidelines, 106, 501
Enzyme histochemistry, of the olfactory mucosa, 437
Enzymes, in cerebrospinal fluid, 276
Eosinophilic neuronal change, 491
Eosinophilic neurons, 9, 192
versus dark neurons, 193
Eosinophils, in cerebrospinal fluid, 279
EPA regulatory requirements, 339. See also Environmental Protection Agency (EPA)
Ependymal lining, 493
Ependymomas, 471
Epidural catheters, 457
Epidural models, 457
Epidural route, for drug delivery, 456–457
Epigenetic events, study of, 287
Epineurium, 231
Epithalamus, 23–24
Epithelia, sensory and ion-transporting, 420–423
Epithelial biopsies, olfactory, 438
Epoxy resin sections, 236
Equine leukoencephalomalacia, 498–499
ERG patterns, 391. See also Electroretinography (ERG)
Erythrocytes
autofluorescence of, 161, 167
in CSF samples, 277–278
in histological preparations, 161
Esthesioneuroblastomas, 441
Estimation principle, 215–216
Ethylenediaminetetraacetic acid (EDTA), 435
Evaluation by omission, 185
Excitatory amino acids (EAAs), 482
Excitotoxicity, 482
Excitotoxic neuronal injury, 482–483
Executive functions, defined, 117
Exencephaly, 16, 80
Expanded clinical observations, 106
Experimental allergic neuritis, 380
Experimental autoimmune encephalomyelitis (EAE), 263
Experimental manipulations, effect on battery components, 120
Experimental methodology, standardization of, 10
Exposure, history of, 488
Expression Analysis Systems Explorer (EASE), 310, 312–313
Exsanguination, for tissue collection, 161
Extensor reflex, 33
External plexiform layer (EPL), 434
Exteroception, 28–30
CNS pathways mediating, 29, 30
subconscious, 38
Extinction, 116
Extraocular tissues, removing, 392
Extrapolation
complications related to, 10
inappropriateness of, 145
interspecies, 10
Extrapyramidal motor pathways, 36
Extrapyramidal system, 35–36
collateral information from, 39
Eyes. See also Extraocular tissues; Intracranial; Ocular; Ocular entries; Ophthalmo- entries; Optic- entries; Retina, Vision; Visual entries
exposure to xenobiotics, 399
fixation, 393–395
harvesting, 328
nonneural structures in, 387–388
plastic sections of, 397
processing, 396–398
removing, 392–393
trimming, 395–396
Eye sectioning, degree of, 332
Eye sections, 395–396
False discovery rate (FDR), 301
False negative neurotoxicity results, 153
False positives/negatives, 191
Familial Alzheimer’s disease (FAD), 126
Fast-twitch (F) muscle fibers, 240–241
Federal Food, Drug and Cosmetic Act (FFDCA), 521
Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), 521
Federal Register, 521
Ferruginated neurons, 468
Ferrugination, 493
Fetal alcohol syndrome (FAS), 345
Fetal calf serum (FCS), 276–277
Fetal Minamata disease (FMD), 345, 346
Fiber size, identifying, 251
Fiber-type-grouping, 241
FITC filter, 167
Fixation, 323–326. See also Supplemental fixation
of ocular tissue, 393–395
of the olfactory mucosa, 434–435
Fixation procedures, 341–343
Fixatives, choosing, 324
Fixative solution osmolarity, 204
Fixed sections, in skeletal muscle sample processing, 243
Flash ERG (fERG), 390, 391
Flash VEP (fVEP), 391
Glial cells, 73
  changes in, 466
Glial-derived molecules, 76
Glial fibrillary acidic protein (GFAP), 168, 183, 197, 275, 335, 476, 492.
  See also GFAP labeling
  enhanced expression of, 488
Glial markers, immunohistochemical procedures to detect, 8
Glial reactions, 80
Gliosis, 352, 466, 476–477
Globoid cell leukodystrophy, 379
Globulins, in cerebrospinal fluid, 275–276
Gluckman, Tracy, xi, 253
Glutamate, 482
Glutamate receptors, 81
Glutaraldehyde, 341–342
Glutaraldehyde fixative, 204
Glutaraldehyde fixation, 324
Glutathione (GSH), 79
Glutathione-S-transferase (GST), 79
Glycogen storage/depletion, identifying, 251–252
GM-2 gangliosidosis, 469
Golgi, Camillo, 4
Good laboratory practices (GLPs), 522–523
Gracile axonal dystrophy (gad) mouse, 378
Graham, Doyle G., xi, 3
Granule cell layer (GCL), 434
Granulomas, 454
  cholesterol, 373
  incidence of, 458
Gravity-feed system, 324–325
Gray matter
  in birds, 20
  cerebellar, 21–22
  cerebral stem, 22
  distribution in the mammalian central nervous system, 17
  hypophyseal, 41
  modalities in, 26–27
  overhandling, 491
  in the rhombencephalon, 21
  in the spinal cord, 19, 24
  vulnerability in humans, 70
Green fluorescent protein (GFP), 263
Grip strength, 107
Gross dissection, tissue acquisition by, 289–290
Gross examination, in diagnostic neuropathology, 463–464
Guard zones, 222
Gundersen, Hans Jørgen G., xi, 209
Gustatory pathway, 31
Gyrencephalic species, 22
Habituation, 106
H&E-stained sections, 192
  examining, 336–337
  paraffin-embedded, 359
H&E staining, 332–334
H&E stains, 152, 160, 167, 171, 172. See also Hematoxylin and eosin (H&E) stain
  advantages and disadvantages of, 176
  interpreting, 349
Hair cells (HCs), 414–423
  damage to, 421–422
  loss of, 419–420, 424
Hall, D. Greg, xi, 159
Handling-induced artifacts, CNS tissue susceptibility to, 191
Head, modalities unique to, 28
Head, Elizabeth, xi, 125
Health, biomarkers of, 115
Hearing, 31–32. See also Ear; Inner ear; Ot- entries
Hearing deficits, 94
Hearing impairment, ototoxicants and, 421
Heavy metals, link to Alzheimer’s disease, 132–133
Hematoxylin and eosin (H&E) stain, 9. See also H&E entries
Hemorrhagic necrosis, 481
Hepatic encephalopathy, 10
Hermanson, John W., xi, 239
Herpesviruses, 469
Heterotopiae, 350–351, 356
n-Hexane, 484
Hexane neuropathy, 484
High-definition microscopic analysis, 203–207
Hippocampal biology, laser capture microdissection and, 290
Hippocampal sclerosis, 125
Hippocampus, 23, 41, 42
  atrophy in dogs, 131
  cell destruction in, 143–145
  domino acid effect on, 146
Histochemical localization, of degenerating neurons, 171–179
Histochemical techniques, conventional, 171
Histological alterations, 199
Histological artifacts, in nervous system tissues, 191–201
Histological evaluations, 160
Histological markers
  of neurotoxicity, 181–190
  versus Fluoro-Jade dyes, 176
Histological measurements, 354–358
Histological preparations, artifacts in veterinary, 490–491
Histological sections, 216
  unstained, 292
History personnel training, 516
Histology processing times, 166
Histopathological examination by microscopy
  EPA guidelines for, 528, 525–526, 531–532
  FDA guidelines for, 533–534
Histopathological lesions, 80
  in inner ear, 421
Histopathology, of the developing nervous system, 349–354
Historical negative control groups, guidelines for, 502–503
HOPE fixative, 287
Hormones, gender-specific, 72
Horner’s syndrome, 98
Horns, spinal cord, 19
Hox gene family, 65
Human aging
  Alzheimer’s disease and, 125–127
  animal models of, 127–132
Human brain aging, pathological lesions in, 126
Human disease, rats as models of, 159
Human neural stem cells (hNSCs), 265
Human Niemann–Pick disease type C, 379
Human olfactory mucosa, 431
  common lesions in, 441
Humans, spinal drug treatment for, 459
Hydraulic extraction, 162
Hydrogen sulfide exposure to, 480
  as metabolic neurotoxicant, 496
Hyperacute neuron damage, 9
Hyperperfusion, 491
Hyperplasia, basal cell, 441
Hypertrophic neuropathy, 375
in the peripheral nervous system, 375
Hypertrophy, RPE, 401, 402, 406
Hypomyelination, detection of, 349–350
Hypomyelogenesis, 378, 379
Hypophyseal gray matter, 41
Hypoplasia, of brain structures, 358
Hypothalamus, 24, 28
role of, 41
Hypoxic damage, 465
Hypoxic patterns, 478–479
Hyten, Monty J., xi, 159

IBA1, 197
IBA1 IHC, 184–185. See also Immunohistochemistry (IHC)
IDPN (β,β’-iminodipropionitrile), 108, 496, 497
IDPN dyskinetic syndrome, 108
illumina Beadchip, 295
Image acquisition/analysis, 299
Imaging. See also Angiography; Autofluorescence entries; Bioluminescent imaging (BLI); Biomicroscopy; Brain imaging studies; Computed tomography (CT); Differential interference contrast (DIC) microscopy; Dopaminergic system imaging; Electroencephalography (EEG); Electroretinography (ERG); Fluorescein angiography (FA); In vivo imaging applications; Light microscopy; Magnetic resonance imaging (MRI); Microscopy; Neural imaging; Neuroimaging modalities; Noninvasive imaging systems; Nuclear imaging; Ophthalmoscopy; Optical coherence tomography (OCT); Optical imaging; Positron-emission tomography (PET); Scanning electron microscopy (SEM); Single-photon-emission computed tomography (SPECT); Transmission electron microscopy (TEM); Ultrasound (US)
of conscious versus unconscious subjects, 256–257
noninvasive, 10
Imaging modalities, 253, 285
Immature brain, transient neural features of, 69
Immature nervous system
tissue reactions of, 80
vulnerability to excitotoxic insults, 81
Immature protective mechanisms, 79
Immersion fixation, 161, 162, 174, 193, 236, 323, 326, 342–343
of the olfactory mucosa, 434
sequential, 349
Immersion-fixed brains, artifacts observed in, 191, 192
Immune/inflammatory neuronal injury, 483
Immune-mediated demyelination, 380
Immunocytochemistry, 277
Immunofluorescence, in multiple labeling, 176
Immunohistochemical markers, for olfactory mucosa elements, 430–432
Immunohistochemical methods, 360
Immunohistochemical stain, 334–335
Immunohistochemistry (IHC), 181, 184. See also CD68 IHC; IBA1 IHC caspase3, 171
Immunohistochemistry processes, 292
advantages and limitations of, 308
Immunophenotyping, 223
Incremental repeated acquisition (IRA) task, 118–119, 120
Indirect ophthalmoscopy, 388
Industrial chemicals, neurotoxic syndromes and, 4
Inflammation, 183–185
brain, 141
of the central nervous system, 469
identifying, 251
optic, 408
Inflammatory lesions, in the peripheral nervous system, 377
Inflammatory neuronal injury, 483
Infolded myelin loops, 373
Ingenuity pathway analysis (IPA), 310, 312
In-house microarray technologies, versus commercial microarray technologies, 296
Injury. See also Brain injury
free-radical stress neuronal, 483–484
generalized patterns of neuronal, 480
immune or inflammatory neuronal, 483
localized patterns of neuronal, 480–482
mechanisms of, 478
to oligodendroglia, 497
toxicant-caused axon, 496–497
transmission-related and excitotoxic neuronal, 482–483
Inner ear. See also Oto- entries
anatomy and physiology of, 413–417
histopathological examination of, 418
histopathological lesions in, 421
methods for studying, 417–418
ototoxicant access to, 417
Inner hair cells (IHCs), 415, 420, 421–423
Inner retina lesions, 403–404
In situ fabrication (ISF), 307
In situ hybridization (ISH) processes, 292
Institutional Animal Care and Use Committee (IACUC), 516
Instrument-induced artifacts, 161
Integration levels, 40–41
Intelligence, 115
Intercellular connections, in the developing nervous system, 77
Internal capsule, 22
Internal plexiform layer (IPL), 434
International Nucleotide Sequence Database Collaboration (INSDC), 310
Interneurons, 33, 34
Internode, 234
Interstitial fluid (ISF)
functions, 271
physiology of, 272–275
physiology of production, circulation, and absorption in, 274–275
Intervertebral foramen, 18
Intracardiac perfusion, 162
Infralaminar nucleated cells, 231
Intramembranous edema, 205
Intraocular neural components. See Ocular components
Intraocular tissues, toxicant availability in, 399
Intraocular vasculature lesions, 404–405
Intrathecal agents, factors affecting the actions of, 452–453
Intrathecal agent toxicology, preclinical assessment of, 453–456
Intrathecal drug delivery, safety of, 459
Intrathecal drugs, structures exposed to, 453
Intrathecal models, 457
Intravascular perfusion, 323, 324
Introduction, of a neuropathology report, 507
Investigative neuropathology studies, 286
In vivo imaging applications
for animal model nervous systems, 253–269
brain imaging in animal subjects, 254–255
magnetic resonance imaging, 259–261
microSPECT and microPET animal model applications, 257–259
nuclear imaging, 254
optical imaging, 261–265
PET imaging, 255–257
ultrasound, 265
Ion-transporting epithelia, agents that affect, 421–423
INDEX

Ipsilateral vestibulospinal tract, 38
Irwin Battery (Irwin’s FOB), 514
Irwin screen, 106
Ischemia/hypoxic damage, 465
Ischemic neuronal necrosis, 491
Ischemic patterns, 478–479
ISF absorption, 275
Isobaric tags for relative and absolute quantitation (iTRAQ), 306
Isotope-coded affinity tags (ICATs), 306
Isotropic uniform random sections, 212
Jensen, Karl F., xi, 501
Jimpy (jp, jp/Y) mouse, 379
Jordan, William H., xii, 159
Jortner, Bernard S., xii, 203
Kainate, 482
Kallman, Mary Jeanne, xii, 513
Kaufmann, Wolfgang, xii, 339
King, Stephen, 505
Kober, Adalbert, 4
Krabbé’s disease, 379
Krinke, Georg J., xii, 365
Kyoto encyclopedia of genes and genomes (KEGG), 310, 312
Kyo–Wistar rats, 379–380
Labeling index, 216, 437
Laboratory collection methods, reviewing, 515
Laboratory information management systems (LIMs), 310, 311
Laboratory species, brain length of, 152
Laboratory tasks, for detecting cognitive deterioration, 130
Lahousse, Stephanie A., xii, 285
Lamina cribrosa, 387
Laminae, spinal cord, 19
Landmark discrimination, 130
Large animal brains, degree of sectioning for, 330
Large animals, brain removal from, 326
Laser capture microdissection (LCM), 290–292. See also LCM entries;
Navigated LCM
Laser capture microdissection systems, characteristics of, 291
Lateral cutaneous sural nerve, harvesting, 327
Lateral olfactory tract (LOT), 434
Lateral ventricles, 17
LCM categories, 291. See also Laser capture microdissection (LCM)
LCM samples, proper handling of, 291–292
Lead exposure, 480
Learning
defined, 116
modeling, 118–119
Lectins, cytotoxic, 376
Lemniscal system, 28
“Length-related gradient of nerve pathology,” 109
Lesion classes, 7
Lesion distribution, regional and tissue specificity of, 493–498
Lesion localization
application of neurological syndromes to, 101
association with neurological signs, 92–96
correlation of clinical signs with, 91–98
signs for, 97
using neurological findings, 89–103
using the “syndrome” concept, 89–101
Lesion patterns, knowledge of, 8
Lesions. See also Focal lesions; Inflammatory lesions; Multifocal
lesions; Neoplastic PNS lesions; Nervous system lesions; Neural
lesions; Neuropathological lesions; OM lesions; Pathological
lesions; Proliferative PNS lesions; Structural lesions; Toxicant-
induced lesions
axon al, 374
cochleotoxic, 422–423
consequences of, 120
histopathological, 80
in human brain aging, 126
in the inner ear, 421
inner retina, 403–404
intraocular vasculature, 404–405
motor cortex, 70
neuropathological, 354
in the olfactory mucosa, 440–441
of the optic nerve, 406–408
photoreceptor, 402–403
resulting from developmental neurotoxicity, 81
of the retinal pigmented epithelium, 405–406
of the tapetum lucidum, 406
toxicant-induced, 401–408
toxicant-induced neural, 9
Lesion types, in toxic neuropathies, 369–374
Leukodystrophies, 378–379
Lewy bodies, 125
Ligand activation studies, 258. See also Radioligands
Light microscopy, 262
Light-producing transgenic animals (LPTAs), 262
Limbic system, 31, 41–42
structures of, 42
Linbus, 41
Lipid hydroperoxides, 483
Lipidosis, 376
Lipid peroxidation, 399, 483
Lipofuscin, 400, 468
Lipoxidation markers, 288
Lissencephalic species, 22
Little, Peter B., xii, 487
Local anesthetics, 453
demyelinating effects of, 458
Localized neuronal injury, 480–482
Locomotor activity, 106
Locomotor system, 28
Locoweed poisoning, 498
Long–Evans rats, 107–108
amphetamine exposure in, 10
Long-term memory, 116–117
amphitoxins exposure in, 10
Loop design, 298
Lost caps, 222
Love, J. G., 451
Lower motor neurons, 15, 32, 33
Luciferase, 262
Luciferase reporters, 262, 263
Lumbosacral syndrome, 100
Lyck, Lise, xii, 209
Lymphoma, 471–472
Lyssavirus, microarray technology and, 302
Macromolecular blots/probes, 286
Macrosopic brain examination, veterinary, 488
Macula, 387
Macular degeneration, age-related, 389, 390
Magnetic resonance imaging (MRI), 129, 131, 253, 255, 259–261.
See also MRI entries
INDEX  

physical and technical concepts related to, 260–261
structural and functional, 261
Magnetic resonance microscopy (MRM), 261, 262
Main olfactory bulb (MOB), 429, 430, 433–434
Malacia, 468, 493. See also Equine leukoencephalomalacia; Nigro-pallidal encephalomalacia; Polioencephalomalacia (PEM)
Malformations, neurotoxicant-induced, 350–351
Malignant anaplastic tumors, 381
Mammalian brain sections, 45
Mammalian central nervous system, distribution of gray matter in, 17
Mammalian cerebellum, 21
Mammalian peripheral nerves, nerve fibers in, 368
Mammalian prosencephalon, embryonic development in, 23
Mammalian species, structural divergence among, 69–71
Mammalian spinal cord, organization of gray matter in, 20
Mammalian spinal nerves, 18
Mammalian ventricular system, 18
MAM model, 358. See also Methylazoxymethanol (MAM)
Manganese as metabolic neurotoxicant, 496
neurotoxicity of, 481
Marchi stage of myelin breakdown, 374
Marginal siderosis, 468
Marijuana smoking, in the monkey model, 121
Markers. See also Appendix 1, Immunohistochemical markers; Olfactory marker protein (OMP)
of chemical change, 181–183
choroid plexus epithelium, 543
droventricle, 543
ependyma, 544
future development of, 538
glia, 542–543
histological, 181–190
neral cell, 542–548
neuroendocrine, 544
neuron, 542
neurotoxicity, 182
of permanent change/damage, 185–187
silas, 186
stem cell, 542
timing of, 154
Massa intermedia thalami, 23
Mass spectrometers, comparison of, 305
Mass spectrometry (MS), 303–304. See also Tandem mass spectrometry (MS/MS)
advantages and limitations of, 308
Matrix-assisted laser desorption/ionization (MALDI), 304–305
advantages and limitations of, 308
Matrix-assisted laser desorption/ionization-imaging mass spectrometry (MALDI-IMS), 305–306
Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS), 309
Measurements
histological, 354–358
morphometrical, 356
Mechanoreceptors, 40
Medial lemniscus, 28
Medical practice, toxicological neuropathology in, 475–486
Medulla, 16
Medulla oblongata, 16, 20
in birds, 21
characteristics of, 346
Medullary narcissus, 451
Melanin granules, 400–401
Memory
aging and, 125
in aging dogs, 130–131
defined, 116–117
Memory tests, 121
Meningial changes, 493
Meningioma, 470
Mercury as metabolic neurotoxicant, 496
toxicity of, 481
Mesencephalic aqueduct, 17, 18
Mesencephalon, 16, 20–21, 65
sectioning scheme for, 465
sections of, 56, 60, 62
Mesencephalon syndrome, 94
Metabolic detoxification, 79
Metabolic neuronopathy, neurotoxicants that cause, 496
Metabolic rate, zonal variations in basal, 8
Metachromatic body, 199
Metathalamus, 23
Metencephalon, 16, 20, 65
sectioning scheme for, 465
Methanol neurotoxicity, 481
Methods. See also Detection methods; Experimental methodology; Gene array technology detection methods; Immunohistochemical methods; Laboratory collection methods; Molecular biology methods; Pathology methods; Principal components analysis (PCA) method; Processing methods; Staining methods/techniques
for detecting neurotoxicity, 181
in a neuropathology report, 507–508
novel fractionator, 221–222
stereological, 210–211
for studying inner ear, 417–418
suppressed silver, 171
for visualizing degenerating neurons, 175–176
Methylazoxymethanol (MAM), 309. See also MAM model
Methyl mercury, as metabolic neurotoxicant, 496
MIAME standards, 311. See also Minimum information about a microarray experiment (MIAME) guidelines
Mice. See also C57BL mice; Enervated (Enr) mouse; Gracile axonal dystrophy (gad) mouse; Jimpy (jp, jp/Y) mouse; Motor neuron degeneration (mnd) mouse; Muscle deficient (mdf) mouse mutant; Niemann–Pick type C (NPC) mouse; Protein zero (P0) mutant mouse; Wasted (wst) mouse; Wobbler (wr, wrb) mouse
genetically altered, 129–130
neural lesions in, 495
senescence-accelerated, 130
Microarray chip technology, 295
Microarray databases, 310, 311
Microarray data validation, 301
Microarray experiment workflow, 294
Microarray Gene Expression Data (MGED) Society, 301
Microarray quality control (MAQC) group, 301
Microarray studies, experimental design in, 295–301
Microarray technologies, 293
eksamples of, 302–303
in-house versus commercial, 296
Microbial infections, microarray technology and, 302
Microdissected cells, uses for, 292
Microglia, 183, 477
normal versus reactive, 184
Microglial cells, 466, 492
Microglial perturbation, 154
microPET, versus microSPECT, 257–258
microPET/microSPECT animal model applications, 257–259
microRNA (miRNA) research, 287
Microscopy, procedures using, 520
microSPECT, versus microPET, 257–258
Microtome block advance (MA), 221–222
Microtomy, 516
Microtubules, 231–234
Microvillar cell (MVC), 430
Micturition, bladder, 41
Midbrain, characteristics of, 345
Midbrain syndrome, 94
Mind, modal model of, 115. See also Cogni- entries
Mineralized neurons, 468
Minimum information about a microarray experiment (MIAME) guidelines, 301. See also MIAME standards
Mitochondria, 231
Mitochondrial dysfunction, 479–480
Mitochondrial function, impaired, 482
Mitral cell layer (MCL), 434
MK-801 (NMDA receptor antagonist), neurotoxicity of, 146–148
Modalities, 25–28
Modeling, of functions and behaviors, 117–120
Molecular analysis
cell number required for, 289
experimental design in, 289
preparing tissue section for, 292
Molecular biology analysis, in skeletal muscle sample processing, 243, 249
Molecular biology methods, classical, 285–286
Molecular elements, examining, 285
Molecular genomics, 537
Molecular imaging, 253
Molecular Interaction (MINT) database, 310, 312
Molecular pathology analyses, sample collection for, 288–289
Molecular signatures, 285
Molecular techniques
gene array technology detection methods, 293–295
gene/protein expression data correlation, 313–314
genomic/proteomic data correlation, 309–312
microarray experiments, 295–301
microarray technology, 293
microarray technology examples, 302–303
nervous system tissue sampling, 288–292
‘omics database integration programs, 312–313
protein analyzing techniques, 303–306
protein quantitation, 306–308
proteomic technologies, 303
proteomic technology examples, 309
in toxicological neuropathology, 285–318
Monkey model, relevance to humans, 121
Monkey operant test battery, 118
Monkeys
imaging, 256–257
interaction with computers, 121
Morphine, spinal delivery of, 453–454. See also Opiates
Morphogens, 78
Morphological effects, in the nervous system, 322
Morphological pathology, development of, 4
Morphologic cell assessment, of cerebrospinal fluid, 277
Morphometrical measurements, 356
Morphometric analysis, 352–353
Morphometric techniques, advanced, 358–361
Moser, Virginia C., xii, 105
Moser Functional Observational Battery (Moser’s FOB), 514
Motion, afferents related to, 30–31
Motivation, assessing aspects of, 117–118
Motor activity, neurotoxic agents that decrease, 488
Motor activity tests, 106
Motor cortex lesions, 70
Motor neuron degeneration (mnd) mouse, 376
Motor neuron disease, 376
differentiating signs of, 99
Motor neurons, 32–33
Motor system, 32–37
collateral information from, 39
Mose's FOB (Moser Functional Observational Battery), 514
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 8, 10, 475, 476. See also 2’-NH2-MPTP
as metabolic neurotoxicant, 496
neurodegenerative disease and, 132
neuronal areas affected by, 147
MPTP damage, 145
MPTP-induced Parkinsonism, 480
MRI applications, 260. See also Magnetic resonance imaging (MRI)
MRI scanner, 260
MRI signal, 260
mRNA (messenger RNA), 289
mRNA expression, 301
mRNA samples, 297
Mucocytes, 199
Müller cells, 386, 390
Mulligan stain, 45, 46
Multifactorial designs, 298–299
Multifocal ERG (mfERG), 390, 391
Multifocal lesions, correlation of clinical signs with, 100
Multiple labeling techniques, 176
Murphy, M. Paul, xii, 125
Muscle, harvesting, 328. See also Skeletal muscle entries
Muscle deficient (mdef) mouse mutant, 376
Muscle deficient (mdef) mouse mutant, 376
Muscle evaluation, 239–252
muscle fiber types, 239–241
muscle fiber regeneration, identifying, 250–251
Muscle fibers, types of, 240–241
Muscle samples, biochemistry and molecular biology processing of, 249
Muscle sampling, approaches to, 250
Myelencephalon, 16, 20, 65
sectioning scheme for, 465
Myelencephalon sections, 56–59
Myelin, in the peripheral nervous system, 234
Myelin artifact, 197
Myelin-associated glycoprotein (MAG), 367
Myelinated axons, 231
Myelinated nerve fiber number, estimation of, 225
Myelination
in the cerebral cortex, 76
in the peripheral nervous system, 69
neural domain function and, 69
Myelin basic protein (MBP), 275, 367
Myelina thalamus, 373
Myelin edema, 373
Myelin formation, 78
Myelin loops, infolded, 373
Myeliningopathies, 368
mutant or engineered models of, 379–380
in the peripheral nervous system, 378–380
primary, 370–371
toxicant-induced, 205
Myelin sheaths, 367
Myelin staining pattern, 349
Myelin synthesis deficiency (msd), 379
Myelocle, 81
Myofiber degeneration, identifying, 250
Myofiber types
  antibodies for detecting, 242
  predominance in skeletal muscles, 242
Myopathic syndrome, 100
Myosin adenosine triphosphatase (mATPase), 239–240
Nader, Michael A., xii, 253
National Center for Toxicological Research (NCTR) Operant Test Battery (OTB), 117
National Library of Medicine (NLM), 311
Navigated LCM, 292. See also Laser capture microdissection (LCM)
Near-infrared spectroscopy (NIRS), 265
Necropsies, 322–328
  fixation in, 323–326
  planning, 323
Necropsy and tissue collection
  EPA guidelines for, 523–524, 529–530, 527–528
  FDA guidelines for, 533
Necropsy personnel training, 515–516
Necrosis, identifying, 250
Negative reinforcement, 116
Negri bodies, 469, 470
Neocortex model, 69
Neopallium, 22
Neoplasms, olfactory, 441
Neoplastic diseases, 470–472
Neoplastic PNS lesions, 380–382
Nerve cell bodies, 365, 367
Nerve fibers, 368
  degeneration of, 205
  pathology of, 492–493
Nerves. See also Nerv- entries
  changes in, 467–468
  fixation of, 326
  harvesting, 489
  peripheral, 229–231
  sampling, 464
Nerve sample quality, factors affecting, 286–288
Nervous system. See also Adult nervous system; Animal nervous systems;
  Autonomic nervous system entries; Central nervous system entries;
  Cranial nerves; Developing nervous system; Direct central nervous system delivery; Enteric nervous system; Immature nervous system;
  Mammalian central nervous system; Peptidergic enteric nervous system; Peripheral nervous system (PNS); Resin-embedded nervous system tissue; Spinal entries; Visceral nervous system
  age-related diseases of, 125
  alterations to, 110
  anatomy of, 45
  complexity of, 63
  early specification of, 64–68
  efficient evaluation of, 169
  evaluation of adverse effects in, 322
  evaluations of, 105–106
  examination of, xix
  function of, 15
  harvesting, 488–489
  high-definition microscopic analysis of, 203–207
  in vivo imaging applications for, 253–269
  macroscopic examination of, 488
  postmortem traumatization of, 199
  somatotopic organization in, 24
  structural domains in, 68
  susceptibility to adverse stimuli, 73
  toxicant-induced damage in, 8
Nervous system cell reactions, theoretical understanding of, 538
Nervous system development
  disruption of apoptosis during, 79
  structural blueprint for, 63
Nervous system diseases
  impact of, xix
  rats as models of, 159
Nervous system dysfunction, behavior as a marker of, 105
Nervous system examination, comprehensive, 321
Nervous system integrity, metrics of, 115
Nervous system lesions, 266
Nervous system studies, changes encountered during, 463
Nervous system tissue(s)
  collecting, 161–162, 288
  evaluation of, 335–337
  histological artifacts in, 191–201
  preserving, 161–162
  resin-embedded, 203, 206
  sampling, 288–292
Nervous system tissue sampling, for molecular analyses, 288–292
Nervous tissue alterations, 199
Nervous tissues
  Neur- entries
  changes in, 467–468
  fixation of, 326
  harvesting, 489
  peripheral, 229–231
  sampling, 464
Neural artifacts
  in formalin-fixed eyes, 392
  histological, 191–201
Neural cell generation, 74
Neural cell markers, 542–548
  alphabetical listing of, 544–548
  cell-type specific listing of, 542–544
Neural cell migration, disruption of, 76
Neural cell production, preceding events affecting, 73
Neural cells
  elimination of, 79
  transducing, 264–265
Neural crest (NC), 16, 75–76
Neural defense systems, 79
Neural development, understanding events in, 64. See also Neurodevelopment
Neural folds, 65
Neural functions
  acquisition of, 69
  across species, 63
Neural imaging, noninvasive, 261
Neural lesions
  development of, 491–493
  toxicant-induced, 9
Neural organization, among mammalian species, 69–71
Neural plate, 63, 65
Neural regions
  localizing, 89
  functions associated with, 63
Neural structure(s), 68
  naming conventions for, 7
  postnatal experiences and, 74
Neural tissues
  adequate assessment of, 10
  staining intensities in, 350
  structural alterations in, 7
  susceptibility to toxic damage, 74
  trimming, 489
Neural tissue samples, collecting, 288
Neural tube, formation of, 16
Neural tube closure defect (NTD), 80
rates of, 81
Neural tube flexures, 65
Neuraxial drug delivery, 451
Neurites, 30, 31, 32, 35
production of, 77–78
Neuritis
experimental allergic, 380
optic, 408
Neuroanatomical abnormalities, mapping by MRI, 261
Neuroanatomic atlases, text-based, 548–549
Neuroanatomy, 168–169. See also Comparative neuroanatomy atlas;
Functional neuroanatomy
avian, 72
Nomenclature, 7. See also Nomenclature, proper
Neuroaxonal dystrophy, 372, 378
Neurobehavioral data, interpretation of, 109–111
Neurobehavioral toxicity, procedures for characterizing, 111
Neurobiological changes, in aging dogs, 131
Neurobiological differences, neurotoxicity bioassays and, 69
Neurobiological investigations, approaches to, 89
Neurobiological parameters, for the brain, 551–554
Neurobiology, primary issues in, 64
Neurobiology references
target organ resources, 551
web-based, 550
Neuroblasts, 68, 74
Neurochemical endpoints, 488
Neurodegeneration, incipient, 9
Neurodegeneration markers, identification of, 177
Neurodegenerative diseases, 81
environmental neurotoxicants and, 132–133
Neurodevelopment, 63–88
anatomical organization in, 63–64
comparative, 69–73
correlative, 68–69
developmental neurotoxicity and, 80–81
nervous system specification in, 64–68
sequence of time during, 73
stage-specific development, 64–67
structural divergence during, 72–73
vascular defects and, 80
vertebrate, 73–74
Neurodevelopmental alterations, 345
Neurodevelopmental dysfunction, 74
Neurodevelopmental events, 64–65
chronological scales governing, 73
timing of, 66–67
Neurodevelopmental histopathology, 349–354
Neurodevelopmental processes, timing and extent of, 65
Neurodevelopmental susceptibility, in later gestation, 81
Neurodevelopmental vulnerability, mechanisms of, 74–80
Neuroembryological approach, advantage of, 64
Neuroepithelia, 68, 74
inner ear, 417
olfactory, 430
Neurofibrillary tangles (NFTs), 126–127, 288
Neurofibromas, 381
Neurofilamentous axonopathy, 378
Neurofilaments, 231
Neurogenesis, 63
in aging dogs, 131
in rodents, 129
across species, 72
Neurohistochemical subpopulations, stains that detect, 183
Neurohistological evaluations, early, 4
Neurohistological processing, 343–346
Neurohistological stains, 181
special, 349
Neurohistologic analysis, focus of, 350
Neuroimaging modalities, noninvasive, 254
Neuroinflammation, imaging in rodents, 258–259
Neurological assessment, sequential diagnostic plan for, 90–91
Neurological conditions, microarray technology and, 302
Neurological deficits, 94
Neurological disease, CSF characteristics in, 278–280
Neurological dysfunction, 3
diagnosing, 9
microscopic lesions and, 77
Neurological evaluations, ante mortem veterinary, 487–488
Neurological examination, 101
Neurological function, differences across strains, 72
Neurological signs, association with lesion localization, 92–96
Neurological syndromes
application to lesion localization, 101
brain-related, 91–98
practical application of, 101
Neurology, clinical training in veterinary, 487
Neuromas, 382
Neuromelanin (NM), 10
Neuromelanin staining, 189
Neuromotor changes, 110
Neuromotor function observations/measurements, 106–107
Neuromotor syndrome, 109
Neuromuscular deficits, 109
Neuronal “fallout,” 493
Neuronal alterations, interpreting, 199–200
Neuronal cell death, detecting, 152. See also Neuronal death
Neuronal connectivity, 74
Neuronal cytoskeleton, 367
Neuronal death, investigating, 322–323
Neuronal degeneration, 196, 476
detection of, 177
Neuronal element disintegration, 185, 186
evaluation of, 187–188
Neuronal elements, staining, 185, 186
Neuronal injury pattern
axonopathy, 484–485
free-radical stress, 483–484
generalized, 480
immune or inflammatory, 483
localized, 480–482
transmission-related and excitotoxic, 482–483
Neuronal loss, in rodents, 129
Neuronal mitochondrial dysfunction, 479–480
Neuronal morphology, 493
Neuronal necrosis, 479
examining stains for, 336
Neuronal necrosis investigation, 322
brain trimming for, 329–330
Neuronal necrosis studies, staining for, 332–335
Neuronal organelles, 233
Neuronal plasticity, 77
Neuronal storage diseases, 100
Neuron definition, in neurotoxicity studies, 141
staining, 397
Ocular toxicological neuropathology
  categories of lesions in, 401–408
  principles of, 398–401
Oddity discrimination learning, 130
Odorant receptor (OR) gene, 432
Oevermann, Anna, xii, 15, 45
Office of Pesticide Programs (OPP), 521
Office of Pollution, Prevention, and Toxics (OPPT), 521
Office of Prevention, Pesticides and Toxic Substances (OPPTS), 521
Olfactory biopsies, 441
Olfactory brain
  architecture and function of, 433–434
  comparative neuropathology of olfactory mucosa and, 441–442
Olfactory bulbs, 17
  in birds, 24
Olfactory cortex (OC), 433
Olfactory ensheathing cells (OECs), 430
Olfactory esthesioblastomas, 441
Olfactory marker protein (OMP), 432
Olfactory mucosa (OM), 429.
  See also OM entries
    agents for preserving, 434–435
    basal cell hyperplasia in, 441
    common lesions in, 440–441
    comparative distribution of, 431
    comparative neuropathology of olfactory brain and, 441–442
    decalcification of, 435
    embedding of, 436
    enzyme histochemistry of, 437
    functional specialization of, 430–433
    macroarchitecture of, 429–430
    microarchitecture of, 430
    neuropathology evaluation of, 436–438, 439–440
    neuropathology of, 438–441
    preparation of, 434–436
    preparing for neuropathology examination, 434–436
    regenerative capacity of, 438–439
    staining of, 436
    trimming, 435
Olfactory mucosal damage
  compounds that induce, 438
  systemically administered agents in, 439
Olfactory neurotoxicity, 438
Olfactory neurotoxicants, 442
Olfactory receptor neurons (ORNs), 430, 432, 434
Olfactory system, 31
  comparative neuropathology of olfactory mucosa and brain, 441–442
  evaluation of olfactory mucosa, 436–438
  neuropathology of, 429–448
  neuropathology of olfactory mucosa and tract, 438–441
  olfactory mucosa and tract, 429–434
  preparation of olfactory mucosa, 434–436
  toxicological neuropathology of vomeronasal organ, 442
Olfactory tract (OT), 433
  neuropathology of, 438–441
Olfactory vesicle, 430
Oligodendroglia, neurotoxicants that injure, 497
Oligodendrogliomas, 471
Oligonucleotide arrays, 295
  prefabricated, 293
OM cell junctions, 439. See also Olfactory mucosa (OM)
OM cell proliferation, evaluating, 436–437
OM degeneration/regeneration, 440–441
  “Omics” databases, programs for integrating, 310, 312–313
Omission, evaluation by, 185
OM lesions, toxicant-induced, 438
OM tumors, toxicant-induced, 441
One-color designs, 298
One-color detection system, 293
Online digital atlas databases, 314
Online Mendelian Inheritance in Man (OMIM) database, 310, 311
On Writing: A Memoir of the Craft (King), 505
Operant behaviors, 117
Operant conditioning, 116
Operant Test Battery (OTB), 117
  monkey, 118
Operant test panel, 118
Ophthalmological research, Fluoro-Jade in, 177
Ophthalmoscopy, indirect, 388
Opiates, 453–455. See also Cocaine
  optical coherence tomography (OCT), 389–390
  optical dissectors, 217, 222–224
  optical fractionators, 219, 222–224
  versus physical fractionators, 222
Optical imaging, 253, 261–265
  using fluorescence, 263
Optic inflammation, 408
Optic nerve
  anatomy of, 387
  clinical assessment of, 388–392
  functional assessment of, 390–392
  harvesting, 327
  quantitative analysis of, 398
  structural assessment of, 388–390
  toxicant-induced lesions of, 406–408
Optic nerve atrophy, 408
Optic nerve fibers, 386
Optic nerve hypertrophy, 402
Optic neuritis, 408
Optic tract, 31
  optimal neuropathological evaluations, 159–160
Organelles, neuronal, 233
Organic solvents, ototoxic effects of, 423
Organisation for Economic Co-operation and Development (OECD)
  testing guidelines, 501
  regulatory requirements, 339
  guidelines, 236, 519
  testing guidelines, 501
Organ of Corti, 414, 416, 417
  damage to, 423
Organogenesis, 63
Organophosphate-induced delayed neuropathy (OPIDN), 496–497
Organophosphate-induced delayed neurotoxicity (OPIDN), 485
Organophosphates (OPs), 485
Organophosphorus (OP) agents, 378
Organs, morphological studies of, 210
Oscillatory potentials (OPs), 390
OTB behavioral profiles, 121
Ototoxic agents. See also Ototoxicants
  classes of, 420–423
  examining the direct effects of, 418
  accessing the inner ear, 417
  ototoxic drugs, effects and actions of, 418–420
  Ototoxic interactions, 423
  ototoxicity, 413
Outer hair cells (OHCs), 415–416, 421–423
  Overlapping syndromes, 100
Oxidative damage
  age-related, 126
  in dogs, 131–132
Oxygen-centered free radicals, 483
Oxytocin, 41

Pain
  sensation of, 29–30
  visceral, 40
Paleocortex model, 69
Paleopallium, 22, 23
Pallium, 22
Pandiri, Arun R., xii, 285
Papilledema, 408
Paraffin-embedded globes, sectioning, 397
Paraffin-embedded H&E-stained sections, 359
Paraffin-embedded sections, 203. See also Paraffin sections
Paraffin embedding, 329, 347 of ocular tissues, 396
Paraffin sections, 219, 236
  staining, 175, 333–334
Paraformaldehyde fixative, 204
Parasympathetic afferents, 40
Parasympathetic system, 28
Parenchymal changes, 468–469
Parietal cortex, 116
Parkinsonism, 481, 482. See also Parkinson’s disease (PD)
  MPTP-induced, 480
Parkinson’s disease (PD), 125
  chemically induced, 132
Paroxysmal syndromes, 101
Pathoclisis, 478
Pathogenesis, early events in, 286
Pathological endpoints
detection of, 140–141
  in neurotoxicity assessment, 139
Pathological evaluations, 105
Pathological lesions
  in animal models of aging, 128
  in human brain aging, 126
Pathology
  ocular component, 385–412
  unmyelinated peripheral nerve fiber, 375
Pathology methods, in nonclinical neurotoxicity studies, 239–252, 339–363
Pathology outcomes, noncorrelation with behavioral outcomes, 110–111
Pathology perspective, limitations of, 9–10
Pathology report contents, guidelines for, 503
Pathology study reports, 505
Pattern VEP (pVEP), 391
Patterson, Tucker A., xii, 115
Peaule, Merle G., xii, 115
Pavlovian conditioning, 116
PCP (1-(1-phenylcyclohexyl)piperidine; phencyclidine), cell destruction by, 143, 145
Peer review reports, 505, 510–511
Pelizaeus–Merzbacher disease, 379
Pelvic abnormalities, 98
Peptide arrays, 307
  advantages and limitations of, 308
Peptidergic enteric nervous system, 367
Peracute neuronal degeneration, versus dark neuron alteration, 197
Percent task completed (PTC), 118, 119, 120
Performance monitoring, in a progressive ratio task, 117–118
Perfusion, unsuccessful, 325
Perfusion fixation, 162, 174, 191, 193, 203–204, 235–236, 324, 341–342, 488
  concerns related to, 515–516
  of the inner ear, 417
  procedure for, 324–326
Perfusion fixatives, 204
Perigangliomas, 380
Perikarya, 31, 39, 40. See also Perikaryons
  optical, 386
Perikaryons, 367
Perineuriona, 381–382
Periodic acid-Schiff (PAS) stain, 244, 248
Peripheral axonopathies, 109
Peripheral benzodiazepine receptors (PBRs), 258–259
Peripheral integration level, 40
Peripheral nerve artifacts, 199
Peripheral nerve fiber pathology, unmyelinated, 375
Peripheral nerve quantification, stereological approaches to, 225
Peripheral nerves, 229–231
  harvesting, 327
  location of, 235
  nerve fibers in, 368
Peripheral nerve sectioning, degree of, 332
Peripheral nerve sections, staining, 335
Peripheral nerve sheath tumor (PNST), 381
Peripheral nerve tissues, 229–237
  anatomy of, 229–234
  embedding of, 236
  fixation of, 235–236
  processing, 235–236
  staining, 236
Peripheral nerve tumors, 380–382
Peripheral nervous system (PNS), 3, 15. See also Peripheral nerve tissues;
PNS entries
  anatomy of, 229–234, 365–367
  axonopathy in, 377–378
  cell structure and function in, 367–368
  correlation of clinical signs and lesion localization in, 100
  hypertrophic neuropathy in, 375
  inflammatory lesions in, 377
  myelin in, 234
  myelinopathy in, 378–380
  nerve fiber types in, 368
  neuronopathy in, 375–377
  neuropathological analysis of, 365–384
  principal lesion types in, 369–374
  proliferative and neoplastic lesions in, 380–382
  sample acquisition from, 234–235, 368–369
  unmyelinated peripheral nerve fiber pathology in, 375
Peripheral neuropathies, rules for analyzing, 370–371
Peripheral parasympathetic neurons, 365
Peripheral somatic nerves, sampling, 234
Peripheral sympathetic neurons, 365
Perls stain, 168
Permanent brain damage, evaluation of, 141
Permanent change/damage, markers of, 185–187
Peroneal nerve, harvesting, 327
Personnel, preparing for neuropathological assessment, 513–517
Personnel training
  histology, 516
  necropsy, 515–516
Perturbations, 183–185
Perturbed microglia, detecting, 184
INDEX 583

PET imaging, 255–257. See also Positron-emission tomography (PET)
Phalaris grass poisoning, 498
Pharmacological effects, in ocular neurotoxicity, 400
Phospholipidosis, drug-induced, 376
Phosphoprotein analysis, 307
Photoreceptor atrophy, 403
Photoreceptor degeneration/regeneration, 401
Photoreceptor integrity, RPE and, 400–403
Physical dissectors, 217, 219
Physical fractionator designs, benefits of, 222
Physical fractionators, 219, 226
  with exhaustive organ sectioning, 220
  sampling designs for, 224
  versus optical fractionators, 222
Physiological monitoring, in MRI experiments, 261
Physiologic cell death, 78–79
Pigments, 468
Pilot data, collecting, 259
Pilot studies, 215
Pittsburgh Compound B (PIB), 259
Plaque deposits, 126–127. See also Aβ plaques
Plasmalemmal linear densities, 231
Plastic-embedded sections, 232
Plastic embedding, 348
  of ocular tissues, 396–397
cis-Platinum (cis-DDP) ototoxicity, 422
Pleocytosis, 279
PNS cell elements, 368. See also Peripheral nervous system (PNS)
PNS fibers, 367–368
PNS ganglia, sampling, 234
PNS samples, special procedures for, 349
PNS specimens, processing, 235–236
Prenatal day, 73
Postnatal day, 73
Post-translational modifications (PTMs), 304
Posture, afferents related to, 30–31
PPD stain, 398
PR 2 + 2 task, 118, 120
Practical neuropathology, 159–170
Precise proprioception, 38
Preclinical evaluations, of spinal drug safety, 456–459
Preclinical spinal injection models, 457
Preclinical studies
  adult nervous system evaluation in, 321–338
  of local anesthetics, 453
  of NMDA blockers, 456
  of opiates, 454
Precocial animals, 340
Prefrontal cortex
  Aβ deposition in, 132
  role in working memory, 116
Prefrontal cortex function, tasks sensitive to, 130
Preganglionic neurons, 328
Primary afferent neurons, 28
Primary axonopathy, 372
Primary brain vessels, 65
Primary demyelination, 372–373, 467–468
Primary myelinopathy, 370–371
Primary neuronal cell cultures, Fluoro-Jade in, 177
Primary sensory neurons, 28, 29
Primate brain sections, 46–57
Primate model, 69
Primates
  cognitive assessments in, 115–123
  imaging, 256–257
  subcortical centers of, 70
Primate vascular pattern, 387
Principal components analysis (PCA) method, 299–300
Procedural memory, 117
Processing methods, for skeletal muscle samples, 243
Profile density, 216–217
Progression, 130
Progressive ratio tasks, 117–118
Proliferating cell nuclear antigen (PCNA), 436, 437
Proliferative lesions, in olfactory mucosa, 441
Proliferative PNS lesions, 380–382
Proportionator, 224–225
Proprioception, 25–28, 30–31
  subconscious, 38–39
  prosencephalic integration level, 41
  prosencephalic vesicle, 65
  prosencephalon, 16, 22–24
  of birds, 24
  embryonic development in mammalian, 23
Protein, integrity of, 287–288
Protein analysis techniques, 303–306
Protein arrays, 306–307
  advantages and limitations of, 308
Protein expression data, anatomical correlation of, 313–314
Protein identification, 307–308
Protein interaction databases, 310, 311–312
Protein-level databases, 310, 311
Protein overexpression, 129
Protein quantitation, 306–308
Protein zero (P0) mutant mouse, 379
Proteins, characteristics of, 345
Pons, characteristics of, 41
Principal components analysis (PCA) method, 299–300
Processing methods, for skeletal muscle samples, 243
Profile density, 216–217
Progressive ratio tasks, 117–118
Proliferating cell nuclear antigen (PCNA), 436, 437
Proliferative lesions, in olfactory mucosa, 441
Proliferative PNS lesions, 380–382
Proportionator, 224–225
Proprioception, 25–28, 30–31
  subconscious, 38–39
  prosencephalic integration level, 41
  prosencephalic vesicle, 65
  prosencephalon, 16, 22–24
  of birds, 24
  embryonic development in mammalian, 23
Protein, integrity of, 287–288
Protein analysis techniques, 303–306
Protein arrays, 306–307
  advantages and limitations of, 308
Protein expression data, anatomical correlation of, 313–314
Protein identification, 307–308
Protein interaction databases, 310, 311–312
Protein-level databases, 310, 311
Protein overexpression, 129
Protein quantitation, 306–308
Protein zero (P0) mutant mouse, 379
Proteolipid protein (PLP), 367
Proteomic analysis, 304
Proteomic data
  correlation with biological functions, 309–312
  validation of, 308
Proteomics techniques, advantages and limitations of, 308
Proteomic technologies, 303
  examples of, 309
Proximal axonopathy, 378
Pseudounipolar DRG cells, 229
Pseudounipolar neurons, 33, 38
Punishment, 116
Purkinje cells/neurons, 21, 22, 39
  counting of, 223
Pyramidal system, 34–35
  collateral information from, 39
Pyridoxine, 376
Pyridoxine neuropathy, 499
INDEX

Quaking (qk) mutant, 379
Qualitative examination, guidelines for, 503
Quantitative analysis, of retinal and optic nerve specimens, 398
Quantitative endpoints, stereological solutions for, 209–228
Quantum dots (QDs), 263–264
Quincke, H., 451
Quinine, 420–421
Rabies, 469
Rabies virus, microarray technology and, 302
Radial glia, 75
Radiculopathy, 380
Radiofrequency (RF), 260
Radioligands, 257.
See also Ligand activation studies
Radiotracers, 257
choosing, 258
Raffaele, Kathleen C., xii, 501
Ramos, Meg, xii, 385
Raphe nuclei, 145
cell destruction in, 143
Rarefaction, 468
Rat brain, organizational features of, 159–160
Rat Brain in Stereotaxic Coordinates, The (Paxinos & Watson), 142
Rat brain sections, 46–58, 148–151
sagittal, 148
Rat brain trimming/processing, 162–166
detailed, 165
four-section, 164
Rat cerebellum sections, 167, 352
Rat CNS processing schedule, 166
Rat olfactory mucosa, 431, 432
antigens in, 432
Rats. See also Kyō–Wistar rats; Long–Evans rats; Sponaneous epileptic rat (SER) mutant; Sprague–Dawley rats; Taiep mutant rat; Tremor (tm/tm) mutant rat; Wistar rat entries; Zitter (zi/zi) mutant rat
in developmental neuropathology design, 339–340
neural lesions in, 494, 495
perfusion fixation of, 341
practical neuropathology of, 159–170
Rat spinal column, processing for microscopic evaluation, 162
Rat spinal cords, collecting, 162
Reactive gliosis, 75
Receptor organs, 15
sampling, 346–347
Recombinant luciferase reporter, 263
Redbook I, 522
Redbook II, 522
Redbook 2000, 522
“Red dead” neurons, 8–9, 192, 491
Red fluorescent protein (RFP), 263
Reference sample design, 298
Reference Sequence (RefSeq) database, 310, 311
Reference trap, 218
Reflex behavior tests, 105
Reflexes, 33–34
Reflex responses, 107
Regeneration, of muscle fiber, 250–251
Regenerative capacity, of olfactory mucosa, 438–439
Regional brain weight measurements, 343
Regional lesion specificity, in veterinary practice, 493–498
Regions of interest (ROIs), imaging, 255
Region-specific neuron production, 73
Region-specific neurogenesis, toxicant exposure during, 8
Regulatory considerations, 501–504
Regulatory guidelines, 519–535
EPA delayed neurotoxicity screening, 527–529
EPA developmental neurotoxicity screening, 529–533
EPA general neurotoxicology screening, 523–527
FDA developmental neurotoxicity screening, 534
FDA general neurotoxicology screening, 533–534
neurotoxicity testing guideline development, 519–521
perspective for neurotoxicity studies, 521–523
scientific definitions extracted from, 523
Regulatory oversight, increase in, 537
Reilly, Christopher M., xii, 385
Remak fibers, 231
Renaut bodies, 375
Reports. See Neuropathology reports
Representative sample, 211–212
Research, fundamental principles of, 7–11
Resin-embedded nervous system tissue, 203, 206
Respiratory center, 40
Response rate (RR), 118, 119, 120
Responsible personnel, in a neuropathology report, 507
Results, in a neuropathology report, 508–509
Retina
anatomy of, 385–387
autofluorescence of, 389
clinical assessment of, 388–392
fixation of, 394
functional assessment of, 390–392
noninvasive structural assessment of, 388–390
quantitative analysis of, 398
sectioning, 397
toxicant-induced lesions of, 401–405
toxicity to, 399
Retinal atrophy, end-stage, 405, 406
Retinal chromophores, photoactivation of, 399
Retinal detachment, 401–402
Retinal diseases, 391
Retinal ganglion cell (RGC) lesions, 403–404
Retinal hemorrhage, 405
Retinal morphology, evaluating, 396
Retinal neurons, 386–387
Retinal neurotoxicity, retinal pigmented epithelium and, 400–401
Retinal OCT images, 390
Retinal pigmented epithelium (RPE), 385–386, 389, 399.
See also RPE hypertrophy
in preserving visual function, 400–401
toxicant-induced lesions of, 405–406
Retinal preservation, for electron microscopy, 397–398
Retinal scarring, 407
Retinal toxicity, indications of, 400
Retinal vasculature, 387–388
Retinol metabolism, 400
Retraction spaces, 191–192
Reversal learning, 130
RF coils, 260
Rhombencephalic vesicle, 65
Rhombencephalon, 16, 20–21, 40
in birds, 21
Risk assessments, for potential neurotoxicants, 3–4
RNA, integrity of, 287. See also Antisense RNA (aRNA); microRNA (miRNA) research; mRNA entries
RNA integrity number (RIN), 287
RNAlater stabilization reagent, 287, 288
Roche Nimblegen microarray chip, 295
Rodent background strain, 129–130
Rodent blood–brain barrier, imaging, 259
Rodent brain
  age-related changes in, 129
  degree of sectioning for, 330
  full coronal sections of, 330
  major subdivisions of, 168–169
  trimming, 490
Rodent eyes, removing, 393
Rodent model, 69
Rodent models
  of human aging and Alzheimer’s disease, 127–130
  for understanding Alzheimer’s disease, 125
  utility of, 128
Rodent neuroinflammation, imaging, 258–259
Rodent olfactory mucosa
  common lesions in, 440–441
  trimming, 435
Rodents. See also Mice; Rat entries
  behavioral aging in, 128
  brain aging in, 129
  brain removal from, 326
  as genetic models of aging, 129–130
  sensory evaluations in, 107
Rodent schwannomas, 382
Rod outer segments (ROS), 400
Rods, 386–387
Rostral surfaces, 166
RPE hypertrophy, 401, 402, 406. See also Retinal pigmented epithelium (RPE)
Rubrospinal tract, 70
Safety, of intrathecal drug delivery, 459
Safety assessments, common flaws in, 145–146
Safety testing spectrum, 140
Sagittal rat brain sections, 148
Sagittal sections, 322
Salicylate, 420–421
Salt toxicity, 499
Salvo, Hope, xii, 519
Sample pooling, 297
Sampling. See also Block sampling fraction (BSF); Brain sampling entries; Disector sampling; Muscle sampling; Nervous system tissue sampling; Non-uniform random sampling; Systematic uniform random sampling (SURS); Temporal sampling;
  Tissue sampling
  CSF, 271, 276–278
  of dorsal root ganglia, 234–235
  effector organ, 346–347
  of nerves, 464
  of nervous system tissue, 288–292
  of peripheral somatic nerves, 234
  PNS, 368–369
  of PNS ganglia, 234
  receptor organ, 346–347
  of skeletal muscle, 242, 348
  of special neural elements, 348
  spinal cord, 348
Sampling designs, for physical fractionators, 224
Sampling rate, 148–151
Sarkar, Sumit, xii, 171
Satellitosis, 466
Scanning electron microscopy (SEM), 417–418
Schmued, Larry, xii, 171
Schwann cell bands, empty, 375
Schwann cells, 16, 231, 232, 233, 234, 367, 369, 467
Schwannomas, 381–382
Sciatic nerve, harvesting, 327
Scientific definitions, from regulatory guidelines, 523
Screening studies, standard design for, 10
Secondary axon degeneration, 372
Secondary brain vesicles, 65
Secondary demyelination, 373–374
Secondary neurological dysfunction, 10
Secondary repair processes, 8
Second-order neurons, 28, 29, 31
Sectioning. See also Sections
  of adult nervous system, 321
  cryostat, 248
  degrees of, 330–332
  of retina, 397
  of spinal cord, 464
  of 3-D structures, 210
Sectioning planes, 162–163
Sectioning scheme, for major brain divisions, 465
Sectioning techniques, 203
Sections. See also Brain sections; CNS sections; Cryosections;
  Fixed sections; Frozen sections; H&E-stained sections; Isotropic uniform random sections; Paraffin sections; Skeletal muscle sections;
  Thick sections; Tissue sections
  cerebellum, 57–58, 60, 62
coronal, 145, 146, 321–322
disector, 220
eye, 395–396
formalin-fixed, 203
H&E-stained, 192
histological, 216, 292
linear measurements of, 354–358
mesencephalon, 56, 60, 62
myelencephalon, 57–60, 62
paraffin-embedded, 203, 219, 236, 333–334
plastic-embedded, 219, 232
rat cerebellum, 167, 352
sagittal, 322
sagittal rat brain, 148
semithin, 203, 204–205
soft plastic, 236
spinal cord, 59, 331–332
telencephalon, 50–56
transverse, 369
vertical, 212
Section thickness, 223
Segmental demyelination, 372–373, 380
Segmentation, basis for, 65
Seizures, 101
Selective sensitivity, 8
Self-ordered spatial search (SOSS) test, 121
Semithin sections, 203, 204–205
Senescence-accelerated mice, 130
Sensitivity, critical periods of, 8
Sensory centers, degree of development in, 68
Sensory epithelia, agents that affect, 420–423
Sensory evaluations, 107
Sensory ganglia, delayed fixation of, 199
Sensory memory, 116
Sensory neurons, in the dorsal root ganglia, 229
Sensory tests, 110
Sequence-level databases, 310–311
Sequential diagnostic plan, for neurological assessment, 90–91
Serial analysis of gene expression (SAGE), 286
Serotonergic axons, 183
Serotonergic neurons, 183
Serotonin, 143
Sexual behavior, 41
Shiverer (shi) mutation, 379
Short-term memory, 116
Short-term memory aspects, modeling, 119–120
“Shotgun” proteomics, 304
Shrinkage effects, 216
Siderosis, 468
Signaling molecules, 78
“Silent neurotoxicity,” 81
Sills, Robert C., xii, 285
Silver, as marker, 186. See also Argyrophilic dark neurons; Cupric silver entries; Suppressed silver entries
Silver disintegration stains, 333
“Simple morphometry,” 353
Single-factor design, 298
Single-photon-emission computed tomography (SPECT), 253. See also microSPECT; SPECT entries
in non-human primate studies, 254
Size concept learning, 130
Size discrimination learning, 130, 132
Skeletal muscle. See also Muscle entries
anatomical and physiological features of, 240
electron microscopy of, 249–250
equipment for freezing, 248
evaluation of, 239
frozen sections of, 245–249
processing, 242–250
sampling, 242
terminology related to, 240
Skeletal muscle fiber type, significance of, 241
Skeletal muscle processing, approaches to, 250
Skeletal muscle sampling, 348
Skeletal muscle samples, processing methods for, 243
Skeletal muscle sectioning, degree of, 332
Skeletal muscle sections
aligning, 243
common processing versus light-microscopic procedures, 246–247
evaluating, 243–244
histochemistry of, 249
interpreting, 250–252
Skeletal muscle tissue, fixation of, 244–245
Skeletomotor neurons, 32
Skinner, B. F., 116
Slide evaluation, 336
Slit lamp biomicroscopy, 388–389
Slow-twitch (S) muscle fibers, 241
Smad2 signaling, 263
Small-fiber neuropathies, 375
“Smart” contrast agents, 260–261
Smell, 31. See also Olfactory entries
Smith–Rudt fixative, 394
Smooth fractionator, 219
Society of Toxicologic Pathologists, 510
Sodium toxicosis, 499
Soft plastic sections, 236
Solvents, ototoxic effects of, 423
Somatic efferent (SE) neurons, 19
Somatic efferents (SEs), 28
Spastic bladder, 99
Spatial learning, 130
Spatial memory task, 130–131
Spatiotemporal studies, 368
Special modalities, 28
Special neural elements, sampling, 348
Special somatic afferent (SSA) nuclei, 21
Special somatic afferents (SSAs), 28
“Special” stains, 9
examining, 337
Special visceral afferents (SVAs), 21, 28
Special visceral efferents (SVEs), 28, 40
Species selection, for developmental neuropathology design, 339–340
Specimen acquisition/processing, for ocular neuropathology studies, 392–397
Specimen preparation, 160–161
SPECT-CT imaging, 257, 258. See also Computed tomography (CT)
Spectrofluorometric profiles, 174
SPECT studies, 255–256
S-phase-specific labeling, 436, 437
Spheroids, 372, 467
Spina bifida, 16, 81
Spinal agents, effect on local tissue, 453
Spinal anesthesia, symptoms of, 453
Spinal block, 451
Spinal bulb, 16
Spinal cord, 16, 18–20
arterial blood supply to, 24, 25
assessing, 464
avian, 72
characteristics of, 346
correlation of clinical signs and lesion localization in, 98–100
damage to, 98
developmental modification of, 70
developmental organization of, 65
fixation of, 463
harvesting, 488–489
intumesence of, 18–19
layering of, 68
measurements of, 553
removal of, 326–327
sampling of, 348
signs for localizing lesions affecting, 99
Spinal cord modalities, 26–27
Spinal cord regions, relative proportions in, 554
Spinal cord sectioning, 464
degree of, 331–332
Spinal cord sections, 59
staining, 335
Spinal cord segments, 18
Spinal drug delivery, 451–452
actions of intrathecal agents, 452–453
animal model of, 457–458
of morphine, 453–454
toxicology of intrathecal agents, 453–456
Spinal drug formulations, concentrations of, 452
Spinal drug safety, preclinical evaluations of, 456–459
Spinal motor tracts, 70
Spinal nerve roots, 230
removal of, 326–327
Spinal nerves, 18, 365
in birds, 20
Spinocerebellar tract, 38–39
Spinocerebellum, 37, 38, 39
Temperature regulation of, 41
sensation of, 28–29
Temporal lobes, 17
Temporal response differentiation (TRD) task, 120
Temporal sampling, in subchronic studies, 154
Temporary threshold shift (TTS), 420–421
Test article effect, on cell numbers, 216
Test guidelines, harmonization of, 522
Testing procedures, for detecting cognitive deterioration, 130
Text-based neuroanatomic atlases, 548–549
Text-based neurobiology references, 549–550
Thalamus, 23
Therapeutic compounds, studies of, xv
“Thick” sections, 203, 204
staining protocols for, 223–224
Third-order neurons, 29
Thoracic nucleus, 38
Thoracolumbar syndrome, 98–100
3-D probes, 217
3-D structures, sectioning, 210
3-NPA (3-nitropropionic acid), brain areas affected by, 143, 144
Three-section brain trimming scheme, 163–164
Tibial nerve, harvesting, 327
Timing behavior, assessing, 120
Timing intervals, for toxicity observations, 153
Tissue acquisition, by gross dissection versus laser capture microdissection, 289–292
Tissue blades, 395
Tissue blocks, 435
subsampling of, 221
Tissue collection, 326–328
in diagnostic neuropathology, 463–464
exanguination for, 161
Tissue embedding, 489–490
Tissue fixation, purpose of, 520
Tissue fixatives, 203
Tissue harvest scheme, 328
Tissue lesion specificity, in veterinary practice, 493–498
Tissue-marking dyes, 164
Tissue morphology, quantitative information about, 209
Tissue perturbations, dark neurons and, 193–194
Tissue preparation, guidelines for, 502
Tissue preservation, inadequate, 160–161
Tissue processing
EPA guidelines for, 524–525, 528, 530–531
FDA guidelines for, 533
Tissue quality evaluating, 515
preservation of, 161
Tissues, postfixation of, 204
Tissue sampling, guidelines for, 502
Tissue sections estimating volume in, 216
thickness of, 166
Tissue selection, 343–344
Tissue shrinkage, 218, 349
avoiding, 216
fractionator and, 219
minimizing, 225
Tissue trimming, training for, 516
Tissue volume deficiencies, 75
Title page, of a neuropathology report, 506
“Toothpaste artifact,” 199
Total cell number. See also Fractionator principle estimating, 216–217
two-step estimation of, 217–218
Touch, sensation of, 28–29
Toothy, Edward, 451
Toxicant delivery, to ocular neural tissues, 398–399
Toxicant-exposed individuals, neurological signs in, 10
Toxicant exposure, critical periods of sensitivity to, 8
Toxicant-induced alterations, biases related to, 9
Toxicant-induced lesions, 401–408
of the optic nerve, 406–408
of the retina, 401–405
of the retinal pigmented epithelium, 405–406
of the tapetum lucidum, 406
versus normal anatomical structures, 350
Toxicant-induced myelinopathy, 205
Toxicant-induced myopathies, 100
Toxicant-induced neuropathology, 3
Toxicant-induced neural lesions, 9
Toxicant-related neuropathologies, 205
Toxicants, consequences of, 120
Toxic axonopathies, 368, 378, 496–497
Toxic exposures, diagnostic neuropathological assessment of, 475
Toxicity body part vulnerability to, 141–142
neuronal morphology in response to, 493
transient nature of, 110
Toxicity observations
time course for, 151–154
timing intervals for, 153
Toxicology, 106
Toxic myelin edema, 380
Toxic myelinopathies, 368
Toxic neuronopathy, 376–377
Toxic neuropathies distribution patterns of, 366
lesion types in, 369–374
Toxic oligodendroglial injury, 497
Toxicological inquiry, progression of, 4
Toxicological neuropathologists, as “super-specialists,” 538
Toxicological neuropathology. See also Toxicologic neuropathology investigations
cerebrospinal fluid analysis in, 271–283
of the ear, 413–428
of the eye, 4–6, 285
founders of, 4–6
fundamental principles of, 7–11
future of, 537–539
historical landmarks in, 5
in medical practice, 475–486
molecular techniques in, 285–318
morphological techniques used in, 6
in neurotoxicity testing, 11
regulatory considerations in, 501–504
requirements for proficiency in, 6
in veterinary practice, 487–500
Toxicological pathology
of ocular components, 385–412
self-instruction in, 6
Toxicologic neuropathology investigations, planning for, 10–11
Toxic Substances Control Act (TSCA), 521. See also TSCA Test Guidelines
Training aids, 515
Training manuals, generating, 515
Transconjunctival enucleation, 393
Transgenic animals, light-producing, 262
Transgenic systems, 262
Transient connections, genesis of, 76–77
Transient radicular irritation (TRI), 453
Transmission electron microscopy (TEM), 203, 205
retinal preservation for, 397–398
in skeletal muscle sample processing, 243
Transmission-related/excitotoxic neuronal injury, 482–483
Transpalpebral enucleation, 392–393
Transverse brain sections, 45–46
Transverse sections, 369
Treatment-related effects
detection of, 503
dose dependence of, 503
Trembler (Tr, allele Tr-J) mutation, 379
Tremor (tm/tm) mutant rat, 379–380
Trigeminal ganglion, harvesting, 327–328
Trimethyl tin (TMT), 108, 422–423
as metabolic neurotoxicant, 496
Trimming. See also Brain trimming entries; Tissue trimming of central nervous system tissue, 463
of eyes, 395–396
of neural tissues, 489
of olfactory mucosa, 435
procedure for, 347–349
of rodent brain, 490
Trimming guide, 329–330
TSCA Test Guidelines, 522. See also Toxic Substances Control Act (TSCA)
Tumors
choroid plexus, 471
malignant anaplastic, 381
neoplastic, 470–472
peripheral nerve, 380–382
Twitcher (twi) mutant, 379
Two-color designs, 298
Two-color detection system, 293
2-D cell profile counts bias in, 217
Two-dimensional gel electrophoresis (2DGE), 303, 309
advantages and limitations of, 308
2-D profile numbers, 225
Two-step estimation, of total cell number, 217–218
Type I/II Alzheimer astrocytes, 467, 477
Type I fibers, 347, 348
Type II fibers, 346–347, 348
Type I muscle fibers, 240
Type II muscle fibers, 240–241
Tyrosine hydroxylase (TH), 359
Ultrasound (US), 253, 265
Ultraceletal pathology, 205
Unbiased cell number estimation, 223
Unbiased counting frame, 217, 218, 225
Unconscious subjects, imaging, 256–257
Uniform random sampling, 211–212
UniGene database, 310, 311
Unit length labeling index (ULLI), 437
Universal Protein Resource (UniProt), 310, 311
University of California Santa Cruz Genome Browser, 310
Unmyelinated axons, 231
Unmyelinated nerve fibers, axonopathy of, 378
Unmyelinated peripheral nerve fiber pathology, 375
Unstained histologic sections, 292
Unsupervised learning, 300
Upper cervical syndrome, 98
Upper motor neurons, 15, 32, 34–36
Uremic encephalopathy, 10
Vascular artifacts, 491
Vasculature, 491
Valentine, Beth A., xii, 239
Valentine, William, xii, 229
Vandevelde, Marc, xii–xiii, 15, 45
Vascular-based lesions, 404–405
Vascular development, 80
Vascular endothelial growth factor (VEGF), 405
Vascular integrity, neurotoxicants that impair, 497–498
Vascular supply, 24–25
Vasculogenesis, 80
Vasogenic edema, 469
Vasopressin, 41
Ventricles, 342
Ventricular system, 16–18, 45, 68
of birds, 17–18
of mammals, 18
Ventricular zone, 74
VEP/VEP recordings, 392
Vernau, Karen M., xiii, 271
Vernau, William, xiii, 271
Verocay body, 381
Vertebral arteries, 24–25
Vertebrate neurodevelopment, principles of, 73–74
Vertebrates, neuron production in, 73
Vertical sections, 212
Vestibular apparatus, 413, 414, 416–417
Vestibular endolymph, 417
Vestibular function, 107
Vestibular nuclei, 37–38
Vestibular pathways, 36, 37–38
Vestibular syndrome, 98
Vestibulocerebellum, 37, 39
Veterinary dietary neurotoxicants, 498–499
Veterinary pathologists, xv
Veterinary practice
ante mortem neurological evaluations, 487–488
artifact identification, 490–491
dietary neurotoxicant identification in, 498–499
macroscopic examination of brain/nervous system, 488
nervous system harvesting, 488–489
neural lesion identification, 491–493
region/tissue specificity issues in, 493–498
tissue embedding and lesion assessment, 489–490
toxicological neuropathology in, 487–500
Vincristine neurotoxicity, 485
Viral diseases, 469–470
Visceral afferent pathways, 40
Visceral efferent pathways, 40
Visceral nervous system, 39–40
Visceral pain sensation, 40
Vision, 31. See also Eye entries
  CNS pathways mediating, 32
  Visual cortex, 31
  across species, 71
Visual deficits, 91–94
Visual evoked potential (VEP), 391–392
Visual streak, 387
Visuospatial working memory, 130
Volume, estimator of, 215–216
Vomeronasal organ (VNO), 429
toxicological neuropathology of, 442
Vomeronasal receptor neurons (VRNs), 442
von Büngner band, 467. See also Bands of Büngner

Waller, Augustus Voney, 369
Wallerian degeneration, 369–372, 467, 492
“Waltzing syndrome.” 108
Wasted (wst) mouse, 376
Water deprivation/sodium ion toxicosis, 499
Web-based neurobiology references, 550
Western blot, advantages and limitations of, 308
White, E. B., 505
White matter, 373
in birds, 20
overhandling, 491
spinal cord, 19–20, 24
Whole-body bioluminescent imaging, 264
Whole-body fixation, 341, 342
Whole eye sections, 396
Whole globes, processing, 396
Wisconsin General Test Apparatus (WGTA), 117
Wistar rat brains, coronal sections of, 350, 351
Wistar rats, 344
Witnessing cell death, 185
Wobbler (wr, wrb) mouse, 376
Working memory, 116
visuospatial, 130

Xenobiotics
brainstem lesions and, 96
eye exposure to, 399
nervous system vulnerability to, 80
neurotoxicity of, 73

Yaksh, Tony L., xiii, 451
Yellow star thistle poisoning, 498
Young, Jamie K., xiii, 159, 513
z-axis calibration study, 222–223
z-axis shrinkage, 224
Zitter (zi/zi) mutant rat, 379–380
Zoniporide, 376